Market Place
Sourcing Support
Nestlé reconsiders peanut allergy program two years after $2.6B buyout
30 Nov 2022 //
ENDPTS
Aimmune to Present Positive Results from Phase 3 POSEIDON Study of PALFORZIA
10 Nov 2022 //
BUSINESSWIRE
Allergy Announces Collaboration with Aimmune Therapeutics to Provide PALFORZIA
13 Oct 2022 //
BUSINESSWIRE
Aimmune Tx to Present New Data for PALFORZIA at the EAACI
30 Jun 2022 //
BUSINESSWIRE
Egg allergy trials halted by Aimmune; Atlas closes its 13th fund for $450M
03 Mar 2022 //
ENDPTS
Aimmune to Publish Pooled Safety Analysis of PALFORZIA Treatment up to 2 Years
16 Feb 2022 //
BUSINESSWIRE
New online community to provide support to chronic pancreatitis patients.
16 Nov 2021 //
PRNEWSWIRE
Aimmune to Present Data at ACAAI on Real-World Burden of Peanut Allergy and more
05 Nov 2021 //
BUSINESSWIRE
Aimmune`s PALISADE-ARC004 Longitudinal Study Showed PALFORZIA
04 Aug 2021 //
BUSINESSWIRE
Aimmune to Present New Two-Year Treatment Satisfaction Data
12 Jul 2021 //
BUSINESSWIRE
Aimmune to Present New Two-Year Treatment Satisfaction Data
09 Jul 2021 //
BUSINESSWIRE
Aimmune Launches the First Real-World Registry Study for Chronic Pancreatitis
08 Jun 2021 //
BUSINESSWIRE
Aimmune Presents New Clinical Data From Pooled Safety Analysis PALFORZIA®
25 Feb 2021 //
BIOSPACE
Leaps by Bayer backs a protein engineering startup taking Aimmune & Nestlé
28 Jan 2021 //
ENDPTS
European Commission approves EU`s first peanut allergy treatment
21 Dec 2020 //
PHARMAFILE
Immune, Announces Signing of Definitive Merger Agreement Between Cytocom
20 Oct 2020 //
BIOSPACE
Aimmune’s peanut allergy med moves toward EU approval
19 Oct 2020 //
PHARMATIMES
Aimmune Receives Positive CHMP Opinion on PALFORZIA® for the Treatment
16 Oct 2020 //
INVESTEGATE
Aimmune Therapeutics: Do Not Tender Your Shares To Nestle
21 Sep 2020 //
SEEKING ALPHA
The central figure in Nestlé`s $2.6B Aimmune buyout? Covid-19
15 Sep 2020 //
ENDPOINTS
Nestlé commences tender offer for Aimmune Therapeutics, Inc.
13 Sep 2020 //
PRNEWSWIRE
Nestlé to acquire remaining shares in Aimmune for $2.6 billion
03 Sep 2020 //
PHARMAFILE
Nestle to buy Aimmune Therapeutics for $2.6 billion
31 Aug 2020 //
CNBC
Largest European Qualitative Study on Peanut Allergy Highlights -VE Impact
24 Aug 2020 //
BUSINESSWIRE
Aimmune Appoints Narinder Singh as Executive Vice President of Operations
06 Jul 2020 //
BUSINESSWIRE
Aimmune says patients begin treatment with peanut allergy drug as COVID-19
02 Jul 2020 //
REUTERS
New Data Show Patients Are Highly Satisfied With and Confident in the Efficacy
08 Jun 2020 //
YAHOO
Aimmune says peanut allergy drug shows benefit after two years
08 Jun 2020 //
REUTERS
Aimmune Therapeutics to Present at the Goldman Sachs 41st Conference
04 Jun 2020 //
BUSINESSWIRE
New PALFORZIA™ Data on Long-Term Safety, Efficacy and PALFORZIA at EAACI 2020
01 Jun 2020 //
BUSINESSWIRE
Largest European Quantitative Study on Peanut Allergy Confirms Significant Need
28 May 2020 //
BUSINESSWIRE
FDA knocks back DBV’s peanut allergy once again
18 Mar 2020 //
PMLIVE
Armed with Nestlé cash, Aimmune grabs experimental food allergy drug from Xencor
06 Feb 2020 //
FIERCE BIOTECH
Aimmune`s controversial peanut allergy med has its FDA nod. Will it sell?
04 Feb 2020 //
FIERCE PHARMA
Aimmune`s Palforzia becomes first treatment for peanut allergy approved in US
01 Feb 2020 //
PRESS RELEASE
FDA decision nears on Aimmune`s contested peanut allergy drug
25 Jan 2020 //
BIOPHARMA DIVE
Aimmune Presents New Peanut Allergy Data
08 Nov 2019 //
BIOSPACE
In 7-2 vote, FDA panel backs Aimmune’s peanut allergy treatment
16 Sep 2019 //
FIERCE BIOTECH
FDA panelists largely endorse Aimmune`s peanut allergy therapy
14 Sep 2019 //
ENDPTS
FDA Allergenic Products Advisory Committee Votes to Aimmune’s PALFORZIA™
13 Sep 2019 //
BUSINESSWIRE
Oxurion reports mixed results from Phase IIa DME study
22 Aug 2019 //
CLINICALTRIAL SARENA
Aimmune Enrolls First Patient in Phase 2 Trial of AR201 for Egg Allergy
21 Aug 2019 //
BUSINESSWIRE
Insitro boosts leadership with Aimmune exec and Pfizer vet
06 Aug 2019 //
FIERCE BIOTECH
Aimmune wins over ICER for peanut allergy product
13 Jun 2019 //
PMLIVE
Aimmune to Present AR101 Data at European Academy of Allergy
24 May 2019 //
BUSINESSWIRE
Phase III results move Aimmune’s peanut allergy drug closer to EU market
27 Mar 2019 //
PHARMA TIMES
European Phase 3 Trial of Aimmune Therapeutics’ AR101 Meets Primary Endpoint
25 Mar 2019 //
BUSINESSWIRE
Aimmune’s peanut allergy immunotherapy clears European PhIII with flying colors
25 Mar 2019 //
ENDPTS
Aimmune drug application confusion leaves investors searching for answers
19 Jan 2019 //
BIOPHARMA DIVE
FDA shutdown no foil for Aimmune’s peanut allergy drug
11 Jan 2019 //
FIERCE BIOTECH
Shutdown has Aimmune waiting on FDA on multiple fronts
09 Jan 2019 //
STAT NEWS
Aimmune Therapeutics Submits BLA to FDA for AR101
21 Dec 2018 //
BUSINESSWIRE
Aimmune Therapeutics Appoints Dr. Jayson Dallas as CEO
12 Jun 2018 //
BUSINESSWIRE
